Piramal Pharma
add_icon

Piramal Pharma

206.64
-6.03
(-2.84%)
Market Cap
27,510.98 Cr
PE Ratio
-90.02
Volume
1,14,39,262.00
Day High - Low
215.85 - 202.01
52W High-Low
218.50 - 132.30
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
27,510.98 Cr
EPS
-2.46
PE Ratio
-90.02
PB Ratio
3.46
Book Value
61.34
EBITDA
1,134.90
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
-3.99
Debt to Equity
0.65
Analyst Rating and Forecast
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Carlyle's stake sale in Piramal Pharma cancelled16 hrs ago
A planned selldown by Carlyle in Piramal Pharma has been cancelled, according to IFR. No further details on the transaction size or timing were disclosed.
neutral
Piramal Pharma: ₹29.81 Cr Block Trade on NSE9 days ago
Piramal Pharma recorded a block trade on NSE worth ₹29.81 crores, involving approximately 1,454,194 shares at a price of ₹205.01 per share.
neutral
Piramal Pharma Restarts Ahmedabad Units After FloodsAug 03, 2026
Piramal Pharma has resumed operations at its Ahmedabad facilities following a temporary interruption caused by flooding, marking a return to normal production activity.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,930.00
#1 4,63,071.65
38.47
#1 61,673.90
12.69
#1 11,565
26.53
47.09
8,477.00
2,25,037.72
77.15
11,067.00
13.95
2,568
65.50
71.85
4,833.00
1,83,831.78
86.03
13,886.20
20.34
2,138
3.28
45.42
1,450.00
1,17,137.57
35.17
29,044.60
2.24
3,870
-39.18
50.74
1,135.20
1,14,227.68
25.48
27,657.90
17.64
5,026
-34.90
50.68
2,235.00
1,02,191.47
#1 18.62
29,038.90
#1 26.75
5,356
16.00
30.04
1,200.00
1,00,160.29
31.62
35,058.60
3.90
4,158
-69.10
49.18
2,425.20
1,00,159.78
48.30
14,636.40
14.85
1,938
29.13
43.34
1,787.30
96,488.57
91.23
6,867.80
22.01
890
#1 123.93
61.64
1,622.10
93,332.05
25.93
34,145.20
5.56
3,503
25.21
55.68
Growth Rate
Revenue Growth
-2.19 %
Net Income Growth
-457.74 %
Cash Flow Change
85.21 %
ROE
-456.25 %
ROCE
-82.19 %
EBITDA Margin (Avg.)
-26.51 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
2,812
2,031
2,124
2,193
2,811
2,379
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
2,193
1,827
1,885
1,985
2,467
2,075
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
619
204
239
208
344
304
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
20 %
6 %
8 %
7 %
10 %
9 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
243
197
203
213
218
224
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
104
86
82
89
83
88
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
273
-79
-46
-94
43
-8
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
119
3
53
42
52
62
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
154
-82
-99
-136
-9
-69
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03
1.16
-0.62
-0.75
-1.03
-0.07
-0.52

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
2026
Total Assets
10,900
12,797
14,523
15,312
15,678
17,965
Fixed Assets
6,106
6,879
7,469
7,990
8,133
8,684
Current Assets
3,649
4,067
4,836
5,465
5,797
7,192
Capital Work in Progress
627
1,172
1,419
1,116
977
1,100
Investments
123
267
639
385
291
437
Other Assets
4,045
4,478
4,996
5,821
6,277
7,745
Total Equity & Liabilities
10,900
12,797
14,523
15,312
15,678
17,965
Current Liabilities
2,490
3,033
3,843
4,369
3,766
4,758
Non Current Liabilities
2,805
3,067
3,906
3,031
3,786
5,044
Total Equity
5,605
6,697
6,774
7,911
8,126
8,163
Reserve & Surplus
4,610
5,511
5,580
6,588
6,801
6,836
Share Capital
995
1,186
1,193
1,323
1,324
1,327

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
2026
Net Cash Flow
110
-177
-32
166
-37
794
Investing Activities
-4,464
-1,737
-1,334
-416
-488
-820
Operating Activities
598
766
484
1,005
892
1,653
Financing Activities
3,977
794
818
-422
-441
-39

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
34.86 %
34.86 %
34.86 %
34.86 %
34.80 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
30.86 %
30.27 %
29.66 %
30.18 %
12.52 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
14.26 %
14.89 %
15.69 %
15.61 %
14.57 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
14.07 %
14.12 %
14.11 %
13.74 %
14.54 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
5.95 %
5.86 %
5.69 %
5.61 %
23.57 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843
4,58,430
4,62,511
4,53,830
4,50,661
4,61,096

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.14 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.1 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 101.95 103.86
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 148.05 151.60
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 157.10 166.30
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 221.30 215.15
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 221.25 224.00
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 214.95 214.90
16 Jul 2025 DIVIDEND Dividend
₹ 0.14 /share
16 Jul 2025 214.90 216.22
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 216.88 202.23
30 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2025 199.95 205.61
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2025 203.60 200.42
28 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2026 168.10 152.45
28 Apr 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Apr 2026 147.45 168.78
29 Jul 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Jul 2026 179.42 193.40
30 Jul 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2026 168.20 195.68

Announcements

Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -Resumption Of Operations At CompanyS Facilities Located At Ahmedabad GujaratAug 03, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2026
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2026
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 30, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJul 29, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2026
Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026Jul 29, 2026
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July 2026Jul 29, 2026
Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock OptionsJul 29, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Temporary Suspension Of Operations At CompanyS Facilities Located At Ahmedabad Gujarat.Jul 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 20, 2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June 2026. Jul 20, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 17, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2026
Business Responsibility and Sustainability Reporting (BRSR)Jul 03, 2026
Reg. 34 (1) Annual Report.Jul 03, 2026
Notice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-26Jul 03, 2026
Closure of Trading WindowJun 29, 2026
Clarification On News Item Appearing On NDTV Profit Captioned - "Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?"Jun 23, 2026
Clarification sought from Piramal Pharma LtdJun 23, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 01, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Digwal Telangana IndiaMay 18, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 10, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 30, 2026
Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 29, 2026
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressApr 28, 2026
Appointment of Company Secretary and Compliance OfficerApr 28, 2026
Announcement under Regulation 30 (LODR)-CessationApr 28, 2026
Results - Financial Year Ended March 31 2026Apr 28, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 28, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationApr 28, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 28, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementApr 28, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Dated April 28 2026Apr 28, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 17, 2026
Board Meeting Intimation for Considering And Approving The Audited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Financial Year Ended 31St March 2026Apr 17, 2026
Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Lexington USAApr 13, 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingApr 06, 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Completion Of Acquisition Of Kenalog® A Branded Commercial Injectable ProductApr 01, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Helios Small Cap Fund Direct-Growth
1.70%
748450
1.00%
0.84%
Bajaj Finserv Small Cap Fund Direct-Growth
2.06%
515049
0.56%
0.56%
ICICI Prudential Conglomerate Fund Direct-Growth
2.06%
65000
0.42%
0.37%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.57%
5366
0.07%
0.04%
JioBlackRock Sector Rotation Fund Direct-Growth
0.09%
-601
0.01%
0.01%
DSP Nifty Healthcare Index Fund Direct-Growth
1.06%
347
0.10%
0.03%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.56%
328
0.07%
0.03%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.28%
281
0.03%
0.02%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.06%
-33
0.01%
0.01%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.19%
-10
0.02%
0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.06%
4
0.01%
0.00%
ICICI Prudential Manufacturing Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.76%
0
0.00%
0.09%
Axis Arbitrage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Balanced Advantage Fund Direct-Growth
0.10%
0
0.00%
0.10%
Axis India Manufacturing Fund Direct-Growth
0.52%
0
0.00%
0.52%
Axis Multicap Fund Direct-Growth
0.34%
0
0.00%
0.34%
Axis Nifty 500 Index Fund Direct-Growth
0.06%
0
0.00%
0.01%
Axis Nifty Smallcap 50 Index Fund Direct-Growth
1.52%
0
0.00%
0.14%
Axis Retirement Fund - Aggressive Plan Direct-Growth
0.38%
0
0.00%
0.38%
ICICI Prudential Smallcap Fund Direct Plan-Growth
0.46%
0
0.00%
0.15%
Axis Value Fund Direct-Growth
0.39%
0
0.00%
0.39%
Bajaj Finserv Consumption Fund Direct-Growth
1.21%
0
0.00%
1.21%
Bajaj Finserv Flexi Cap Fund Direct-Growth
1.37%
0
0.00%
0.18%
Bajaj Finserv Healthcare Fund Direct-Growth
6.60%
0
0.00%
0.56%

Technical Indicators

RSI(14)
Neutral
73.52
ATR(14)
Volatile
7.51
STOCH(9,6)
Overbought
80.70
STOCH RSI(14)
Neutral
72.61
MACD(12,26)
Bullish
1.13
ADX(14)
Very Strong Trend
54.65
UO(9)
Bearish
49.32
ROC(12)
Uptrend And Accelerating
9.95
WillR(14)
Overbought
-15.44

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Chairperson NameNandini Piramal